Sarcopenia is present in a considerable proportion of patients with MIBC undergoing upfront cisplatin-based chemotherapy before planned RC. SMI decreases during treatment, but neither baseline SMI nor its kinetics is associated with response to chemotherapy.
Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer / Stangl-Kremser, Judith; Mari, Andrea; D'Andrea, David; Kimura, Shoji; Resch, Irene; Shariat, Shahrokh F.; Klatte, Tobias. - In: UROLOGIA INTERNATIONALIS. - ISSN 0042-1138. - STAMPA. - 101:(2018), pp. 197-200. [10.1159/000489013]
Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer
Mari, Andrea;
2018
Abstract
Sarcopenia is present in a considerable proportion of patients with MIBC undergoing upfront cisplatin-based chemotherapy before planned RC. SMI decreases during treatment, but neither baseline SMI nor its kinetics is associated with response to chemotherapy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
38.pdf
Accesso chiuso
Descrizione: Articolo principale
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
130.49 kB
Formato
Adobe PDF
|
130.49 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
